Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRRXOTCMKTS:IPCIFNASDAQ:LGVNOTCMKTS:LTUS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRRXDURECT$0.67+0.0%$0.61$0.48▼$1.74$20.69M0.6443,381 shs16,699 shsIPCIFIntellipharmaceutics International$0.00$0.00▼$0.15$4.96M1.5312,042 shsN/ALGVNLongeveron$1.32+1.2%$1.35$1.14▼$6.40$19.63M0.211.38 million shs41,898 shsLTUSLotus Pharmaceuticals$0.01+4.5%$0.01$0.00▼$0.01$18.51M-2.4834,004 shs25,000 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRRXDURECT+0.02%+7.29%+16.56%-14.83%-47.91%IPCIFIntellipharmaceutics International0.00%0.00%0.00%0.00%-99.93%LGVNLongeveron+1.15%+1.15%+11.44%-6.07%-20.30%LTUSLotus Pharmaceuticals+4.48%-6.67%+18.64%+27.27%+112.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDRRXDURECT0.5687 of 5 stars0.02.00.04.41.10.00.0IPCIFIntellipharmaceutics InternationalN/AN/AN/AN/AN/AN/AN/AN/ALGVNLongeveron3.7783 of 5 stars3.65.00.00.02.61.71.3LTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRRXDURECT 2.00HoldN/AN/AIPCIFIntellipharmaceutics International 0.00N/AN/AN/ALGVNLongeveron 3.25Buy$8.67559.06% UpsideLTUSLotus Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRRXDURECT$2.03M10.19N/AN/A$0.29 per share2.30IPCIFIntellipharmaceutics International$660K0.00N/AN/A($0.32) per share0.00LGVNLongeveron$2.23M8.82N/AN/A$1.47 per share0.89LTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRRXDURECT-$8.32M-$0.15N/AN/AN/A-91.54%-267.36%-64.00%8/12/2025 (Estimated)IPCIFIntellipharmaceutics International-$2.89M-$0.16N/AN/AN/AN/AN/AN/AN/ALGVNLongeveron-$15.97M-$6.28N/AN/AN/A-760.72%-85.07%-70.74%8/13/2025 (Estimated)LTUSLotus Pharmaceuticals$110KN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDRRXDURECTN/AN/AN/AN/AN/AIPCIFIntellipharmaceutics InternationalN/AN/AN/AN/AN/ALGVNLongeveronN/AN/AN/AN/AN/ALTUSLotus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRRXDURECTN/A1.231.22IPCIFIntellipharmaceutics InternationalN/AN/AN/ALGVNLongeveronN/A5.615.61LTUSLotus PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRRXDURECT28.03%IPCIFIntellipharmaceutics InternationalN/ALGVNLongeveron10.01%LTUSLotus PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipDRRXDURECT3.20%IPCIFIntellipharmaceutics International1.76%LGVNLongeveron11.20%LTUSLotus PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRRXDURECT8031.04 million30.05 millionOptionableIPCIFIntellipharmaceutics International1033.09 million32.51 millionNot OptionableLGVNLongeveron2014.93 million13.26 millionNot OptionableLTUSLotus Pharmaceuticals2302.64 billionN/ANot OptionableIPCIF, LTUS, LGVN, and DRRX HeadlinesRecent News About These CompaniesGeely’s Lotus says ‘no plans’ to close any factoryJuly 2 at 12:28 AM | msn.comLotus Pharmaceutical Co Ltd (1795) - Investing.com UKJune 26, 2025 | uk.investing.comLotus Therapeutics Appoints Leslie Felix as Chief Growth OfficerJune 4, 2025 | finance.yahoo.comSperanza Therapeutics Launches New Division to Help Pharma Manufacturers Adapt to Market ShiftsApril 23, 2025 | finance.yahoo.comLotus Pharmaceutical becomes strategic partner for…February 5, 2025 | pharmiweb.comPTaiwan’s pharma firm Lotus acquires edema medicine rights in Vietnam from SanofiJanuary 9, 2025 | theinvestor.vnTlotus exchangeDecember 28, 2024 | everythingexperiential.businessworld.inEBoryung, Lotus Pharma signs CDMO deal on anticancer injectionDecember 12, 2024 | kedglobal.comKLotus Pharmaceuticals Inc Price / BookNovember 20, 2024 | investing.comLotus Bakeries: When Growth Potential Meets Pricey ExpectationsNovember 13, 2024 | seekingalpha.comUSA Knotless Surgical Sutures Market Expected to Reach USD 258.7 Million by 2033 at a 3.6% of CAGRNovember 1, 2024 | fmiblog.comF20 Shows Like ‘Black Mirror’ That’ll Definitely Mess with Your HeadNovember 1, 2024 | yahoo.comLotus Bakeries: A Sweet Business With Exponential GrowthOctober 27, 2024 | seekingalpha.comA Forbidden Lotus Elise Rival Is for Sale in the U.S. Right NowOctober 24, 2024 | msn.comNatasha Rothwell Opens Up About 'The White Lotus' Season 3, 'How to Die Alone' & MoreOctober 23, 2024 | msn.comLotus Resources Plans Equity Raise for Uranium ProjectOctober 22, 2024 | markets.businessinsider.comLotus of Love Cancer IncOctober 20, 2024 | msn.comThis 90s-Era GM-Lotus Mashup Was The Ultimate Sleeper SedanOctober 19, 2024 | topspeed.comTWhy Romantics Love the Lotus Sex Position, According to a SexologistOctober 9, 2024 | popsugar.comPTopic: @lotusOctober 9, 2024 | arstechnica.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeIPCIF, LTUS, LGVN, and DRRX Company DescriptionsDURECT NASDAQ:DRRX$0.67 +0.00 (+0.02%) As of 07/3/2025 01:00 PM EasternDURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.Intellipharmaceutics International OTCMKTS:IPCIFIntellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. In addition, it provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. Intellipharmaceutics International Inc. was founded in 1998 and is based in Toronto, Canada.Longeveron NASDAQ:LGVN$1.32 +0.02 (+1.15%) Closing price 07/3/2025 01:00 PM EasternExtended Trading$1.31 -0.01 (-0.68%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.Lotus Pharmaceuticals OTCMKTS:LTUS$0.0070 +0.00 (+4.48%) As of 07/3/2025 11:21 AM EasternLotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case How a Government Loan Changes the Game for Plug Power Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
